Between the Lines is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from oncologists and advanced practice providers on published, peer-reviewed content.
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study
Between the Lines: Recent Updates in Treatment and Strategies for Managing Adverse Events in Multiple Myeloma
Tailored Intervention Aids Distress, Recovery After Breast-Conserving Surgery
Oncology Nurses Report Heavier Workloads in the Wake of the COVID-19
Early Infection Post Cilta-Cel Emphasizes Need for TRAE Monitoring in MM
Multidisciplinary Training of BiTE-Associated AEs Increases Safety in Outpatient Setting